INTS Stock Price, Intensity Therapeutics, Quote, Chart

Market Summary

USD4.90-0.20

Delayedas of 17 May 2024, 12:23 pm

-3.92%

INTS Stock Price

View Fullscreen

INTS RSI Chart

INTS Valuation

Market Cap

69.9M

Price/Earnings (Trailing)

-5.07

Price/Free Cashflow

-6.55

INTS Price/Earnings (Trailing)

INTS Profitability

Return on Equity

-142%

Return on Assets

-111.26%

Free Cashflow Yield

-15.26%

INTS Fundamentals

INTS Earnings

Earnings (TTM)

-13.8M

Earnings Growth (Yr)

-244.54%

Earnings Growth (Qtr)

-45.14%

Breaking Down INTS Revenue

52 Week Range

5.28

(Low)(High)

Last 7 days

37.5%

Last 30 days

26.1%

Last 90 days

72.3%

How does INTS drawdown profile look like?

INTS Financial Health

Current Ratio

4.43

INTS Investor Care

Shares Dilution (1Y)

302.02%

Diluted EPS (TTM)

-1.51

Which funds bought or sold INTS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-48,865	75,400	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-52.00	-	-%
May 15, 2024	Sentinus, LLC	new	-	149,822	149,822	0.05%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	37,486	37,486	-%
May 15, 2024	Royal Bank of Canada	reduced	-69.57	-	-	-%
May 14, 2024	One Charles Private Wealth Services, LLC	new	-	165,360	165,360	0.07%
May 14, 2024	Qube Research & Technologies Ltd	added	80.03	4,877	57,694	-%
May 13, 2024	UBS Group AG	added	502	11,372	15,657	-%
May 13, 2024	HRT FINANCIAL LP	sold off	-100	-273,000	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	4.98	-141,137	247,659	-%

Are Funds Buying or Selling INTS?

Are funds buying INTS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INTS

No. of Funds

Unveiling Intensity Therapeutics, Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	bender lewis h	16.1%	2,245,000	SC 13G

Recent SEC filings of Intensity Therapeutics, Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	4	Insider Trading
May 15, 2024	3	Insider Trading
May 10, 2024	8-K	Current Report
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 19, 2024	8-K	Current Report
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	10-K	Annual Report
Mar 07, 2024	4	Insider Trading

Peers (Alternatives to Intensity Therapeutics, Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Intensity Therapeutics, Inc News

Latest updates

Intensity Therapeutics, Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

Balance Sheet					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2022Q4
Assets	-28.3%	12.00	17.00	17.00	18.00	2.00
Current Assets	-27.8%	11.00	15.00	17.00	18.00	1.00
Cash Equivalents	-12.8%	7.00	9.00	7.00	0.00	1.00
Liabilities	-35.0%	3.00	4.00	1.00	3.00	7.00
Current Liabilities	-36.4%	3.00	4.00	1.00	3.00	7.00
Shareholder's Equity	-26.1%	10.00	13.00	16.00	15.00	-15.10
Retained Earnings	-9.1%	-55.12	-50.51	-47.34	-43.69	-38.65
Additional Paid-In Capital	1.8%	65.00	64.00	63.00	60.00	24.00
Shares Outstanding	0.0%	14.00	14.00	14.00	13.00	3.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)								(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2
Cashflow From Operations	-361.0%	-4,366	-947	-5,118	-238	-901	-	-	-
Share Based Compensation	173.3%	1,155	423	351	312	312	-	-	-
Cashflow From Investing	15.5%	3,260	2,821	-	-	-	-	-	-
Cashflow From Financing	165.8%	8.00	-12.16	20,521	-241	205	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INTS Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 2,815	$ 774
General and administrative	1,928	480
Total operating expenses	4,743	1,254
Loss from operations	(4,743)	(1,254)
Other income (expense):
Interest income	140	0
Interest expense	0	(83)
Other income	0	1
Net loss	$ (4,603)	$ (1,336)
Loss per share, basic (in dollars per share)	$ (0.34)	$ (0.39)
Loss per share, diluted (in dollars per share)	$ (0.34)	$ (0.39)
Weighted average number of shares of common stock, basic (in shares)	13,709,487	3,410,103
Weighted average number of shares of common stock, diluted (in shares)	13,709,487	3,410,103

INTS Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

^[1]

Current assets:

Cash and cash equivalents

$ 7,458

$ 8,556

Marketable debt securities

3,039

6,220

Prepaid expenses and other current assets

672

688

Total current assets

11,169

15,464

Right-of-use asset, net

141

147

Other assets

1,098

1,684

Total assets

12,408

17,295

Current liabilities:

Accounts payable

1,219

3,048

Accrued expenses

1,274

891

Lease liability, current portion

26

20

Total current liabilities

2,519

3,959

Other long-term liabilities

36

Lease liability, net of current portion

131

138

Total liabilities

2,686

4,133

Commitments and contingencies

Stockholders' equity:

Preferred stock, issued

0

Common stock, issued

1

Additional paid-in capital

64,839

63,676

Accumulated deficit

(55,118)

(50,515)

Total stockholders’ equity

9,722

13,162

Total liabilities and stockholders’ equity

$ 12,408

$ 17,295

[1]	Derived from audited financial statements

About Intensity Therapeutics, Inc

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. Its lead product candidate includes INT230-6, a clinical trial for the treatment of refractory solid tumors and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. The company was incorporated in 2012 and is headquartered in Westport, Connecticut.

0

CEO	Mr. Lewis H. Bender M.A., M.B.A., M.S.
WEBSITE	https://intensitytherapeutics.com
INDUSTRY	Biotechnology

Intensity Therapeutics, Inc Frequently Asked Questions

What is the ticker symbol for Intensity Therapeutics, Inc? What does INTS stand for in stocks?

INTS is the stock ticker symbol of Intensity Therapeutics, Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intensity Therapeutics, Inc (INTS)?

As of Thu May 16 2024, market cap of Intensity Therapeutics, Inc is 69.93 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INTS stock?

You can check INTS's fair value in chart for subscribers.

What is the fair value of INTS stock?

You can check INTS's fair value in chart for subscribers. The fair value of Intensity Therapeutics, Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Intensity Therapeutics, Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INTS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Intensity Therapeutics, Inc a good stock to buy?

The fair value guage provides a quick view whether INTS is over valued or under valued. Whether Intensity Therapeutics, Inc is cheap or expensive depends on the assumptions which impact Intensity Therapeutics, Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INTS.